BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
M Reig, A Forner, J Rimola, J Ferrer-Fàbrega… - Journal of …, 2022 - Elsevier
There have been major advances in the armamentarium for hepatocellular carcinoma
(HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and …
(HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and …
Management of hepatocellular carcinoma: a review
ZJ Brown, DI Tsilimigras, SM Ruff, A Mohseni… - JAMA …, 2023 - jamanetwork.com
Importance Hepatocellular carcinoma (HCC) is the sixth most common malignancy and
fourth leading cause of cancer-related death worldwide. Recent advances in systemic and …
fourth leading cause of cancer-related death worldwide. Recent advances in systemic and …
AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
This guidance document provides an updated approach to the prevention, diagnosis, and
treatment of hepatocellular carcinoma (HCC). The prior American Association for the Study …
treatment of hepatocellular carcinoma (HCC). The prior American Association for the Study …
Targeting angiogenesis in oncology, ophthalmology and beyond
Angiogenesis is an essential process in normal development and in adult physiology, but
can be disrupted in numerous diseases. The concept of targeting angiogenesis for treating …
can be disrupted in numerous diseases. The concept of targeting angiogenesis for treating …
Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology
AB Benson, MI D'Angelica, DE Abbott… - Journal of the National …, 2021 - jnccn.org
The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging,
treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and …
treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and …
Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy
Hepatocellular carcinoma (HCC) mortality rates are increasing globally, and particularly in
the Western world. Cirrhosis remains the predominant risk factor for HCC. However …
the Western world. Cirrhosis remains the predominant risk factor for HCC. However …
Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update
M Kudo, Y Kawamura, K Hasegawa, R Tateishi… - Liver cancer, 2021 - karger.com
Abstract The Clinical Practice Manual for Hepatocellular Carcinoma was published based
on evidence confirmed by the Evidence-based Clinical Practice Guidelines for …
on evidence confirmed by the Evidence-based Clinical Practice Guidelines for …
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality and
has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided …
has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided …
Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III …
QJ Li, MK He, HW Chen, WQ Fang, YM Zhou… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE In a previous phase II trial, hepatic arterial infusion chemotherapy (HAIC) with
infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) yielded higher treatment …
infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) yielded higher treatment …
90Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE …
E Dhondt, B Lambert, L Hermie, L Huyck… - Radiology, 2022 - pubs.rsna.org
Background Transarterial chemoembolization (TACE) is the recommended treatment for
intermediate hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver …
intermediate hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver …